The effects of Lyprinol(®) on delayed onset muscle soreness and muscle damage in well trained athletes: a double-blind randomised controlled trial.
OBJECTIVE
The aim of the study was to determine if Lyprinol(®) is effective in reducing pain, indicators of inflammation and muscle damage, and in turn improving performance in well trained athletes suffering from delayed onset muscle soreness (DOMS).


METHODS
A double blind randomised placebo controlled trial.


METHODS
Twenty well trained male volunteers, matched by VO(2max) were randomly assigned to consume 200mg of Lyprinol(®) or an indistinguishable placebo daily for 8 weeks prior to a downhill treadmill running episode designed to induce DOMS.


METHODS
Performance measures (Kin-Com, counter movement and squat jump), pain assessments (visual analogue scale, algometer) and blood analyses (Interleukin-1, Interleukin-6, Interleukin-10, tumour necrosis factor-α, C-reactive protein, myoglobin, creatine kinase) were assessed at 7 time points over 5 days (pre, post, 4, 24, 48, 72 and 96h after the downhill run).


RESULTS
No statistically significant differences were identified in any parameters between the active and placebo groups at any time point.


CONCLUSIONS
After 2 months ingestion of Lyprinol(®) at the currently recommended dosage (200mg/day) and a demanding eccentric exercise intervention, Lyprinol(®) did not convincingly affect DOMS and indicators of muscle damage.
National Institute of Sport Studies, University of Canberra, Australia. Kate.Pumpa@canberra.edu.au
Kate L
KL
Pumpa
Kieran E
KE
Fallon
Alan
A
Bensoussan
Shona
S
Papalia
D000293:Adolescent; D000328:Adult; D000818:Animals; D054874:Athletic Performance / Q000502:physiology*; D049872:Bivalvia / Q000737:chemistry*; D003402:Creatine Kinase / Q000097:blood; D004311:Double-Blind Method; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood; D008055:Lipids / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D009068:Movement; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000502:physiology; D009140:Musculoskeletal Diseases / Q000097:blood / Q000517:prevention & control; D059352:Musculoskeletal Pain / Q000097:blood / Q000517:prevention & control*; D009211:Myoglobin / Q000097:blood; D010101:Oxygen Consumption; D010147:Pain Measurement; D012420:Running / Q000502:physiology*; D016896:Treatment Outcome; D055815:Young Adult
D018836:Inflammation Mediators; D008055:Lipids; D009211:Myoglobin; C418997:lyprinol; D003402:Creatine Kinase